Antidepressant Selection in Primary Care

Size: px
Start display at page:

Download "Antidepressant Selection in Primary Care"

Transcription

1 Antidepressant Selection in Primary Care Rebecca D. Lewis, DO OOA Summer CME Oklahoma City, OK 6 August 2017 Objectives Understand the epidemiology of depression. Recognize factors to help choose antidepressants. Identify side effect profile of common antidepressants. Identify patient populations that have unique antidepressant needs. 1

2 Disclosures None Epidemiology 1 in 11 patients meet criteria for depression Antidepressants are 3 rd most common med class in US Depression is 2 nd leading cause of disability in US Can contribute to conditions such as IBS, chronic pain, and others 2

3 Definition DSM-V: 5+ of the following symptoms for 2-week period and a change from previous functioning; AND at least one of the symptoms is either depressed mood or loss of interest or pleasure. The symptoms cause clinically significant distress or impairment in social, occupational or other important areas of functioning. Sx not due to effects of a substance or a general medical condition. Rule out anemia, hypothyroid, electrolyte d/o, etc. Depression Symptoms Sleep Interest Guilt Energy Concentration Attention Psychomotor Suicide 3

4 Depression Symptoms Positive On Edge Agitation Anxiety Insomnia Negative - Blah Flat affect Hypersomnolence Fatigue Somatic Symptoms Abdominal Pain Back Pain Constipation Fatigue Headache Insomnia/Hypersomnia Joint Pain Neck Pain Weakness 4

5 Depression Risk Factors Chronic Medical Illness Chronic Pain High Daily Stress Levels Personal or Family Hx of Depression Female Low SES Single/Divorced/Widowed TBI Depression Screening USPSTF Grade B Recommendation Screening adults for depression when staff-assisted depression care supports are in place to assure accurate diagnosis, effective treatment, and followup. 5

6 Depression Assessment PHQ-2 PHQ-9 Geriatric Depression Scale (5 and 15 item) Edinburgh Postpartum Depression Scale Tools are great for screening and follow up Side Effects 2/3 of pts will have a side effect Education on side effects is key to compliance Most Common Diarrhea N/V Sexual Dysfunction Somnolence Weight Gain 6

7 Common Prescribing Errors One size fits all medicine Treating all meds in one class the same Giving up after one med Under dosing Choosing a med you are not comfortable with starting or stopping Choosing An Antidepressant Things to consider: Predominating symptoms Cost Side Effect Profile Any desired side effects? Coexisting conditions Patient Preference 7

8 Antidepressant Classes Selective Serotonin Reuptake Inhibitor (SSRI) Sertraline, Citalopram, Escitalopram, Paroxetine, Fluoxetine, Vortioxetine Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) Venlafaxine, Desvenlafaxine, Duloxetine Serotonin Modulators Trazodone, Nefazodone, Vilazodone Tricyclic Antidepressants (TCA) Amitriptyline, Nortriptyline, Imipramine, Doxepin Monoamine Oxidase Inhibitors (MAOI) Phenelzine Atypicals Bupropion, Mirtazapine SSRIs One of 1 st line meds Easy to switch from one to another Easy to wean off Longer Half-lives, especially Fluoxetine Lowest side effect profile Side Effects: N/V/D, headaches, weight gain, libido decrease, diaphoresis, bruxism Titrate up to therapeutic dose to decrease side effects Effectiveness at 2-4 weeks Time of day to take: AM or PM 8

9 SNRIs Another 1 st line med Harder to wean off and switch Lower side effect profile Side Effects: N/V/D, headaches, libido decrease, HTN, dry mouth, significant w/d sx with dose decrease, diaphoresis Titrate up to therapeutic dose to decrease side effects Effectiveness at 2-4 weeks Time of day to take: AM or PM tends toward AM Bupropion Another 1 st line med Lower side effect profile Contraindications: Eating disorders, seizure disorder, caution with alcohol abuse Side Effects: N/V/D, headaches, HTN, dry mouth, seizures Titrate up to therapeutic dose to decrease side effects Effectiveness at 2-4 weeks Time of day to take: AM or PM tends toward AM 9

10 Mirtazapine Another 1 st line med Higher side effect profile More effective for sleep at lower doses Side Effects: Weight gain, increased cholesterol, drowsiness, appetite increase Fastest effectiveness of all antidepressants at hours Time of day to take: PM Serotonin Modulators 2 nd line Side Effects: Orthostatic hypotension, priapism (trazodone), hepatotoxicity (nefazodone), sedation More effective as antidepressant at higher doses, sedative at lower doses Effectiveness at 2-4 weeks, sedation effects immediate Time of day to take: PM 10

11 TCAs 2 nd line High side effect profile, easy OD Side Effects: arrhythmia, constipation, dry mouth, sedation, delirium, sexual side effects, bladder retention, diaphoresis, weight gain Titrate up to therapeutic dose to decrease side effects Effectiveness at 2-4 weeks, sedation immediate Time of day to take: PM MAOIs Last line med Require a 2-6 week washout period before starting or stopping MAOI Dietary restrictions Side Effects: Orthostatic hypotension, anorgasmia, HTN crisis, severe serotonin syndrome Effectiveness at 2-12 weeks Time of day to take: AM or PM tends toward PM 11

12 Best for Negative Sx Meds with increased noradrenergic effect Better to avoid in high anxiety patients Activating medications: Some SSRIs, SNRIs, Bupropion Includes: Bupropion Venlafaxine Desvenlafaxine Fluoxetine Duloxetine Sertraline Best for Positive Sx More dopaminergic and serotonergic effect Better for high anxiety patients Calming Medications Include: Escitalopram Citalopram Paroxetine Vorioxetine 12

13 Weight Effects Weight Gain Mirtazapine TCAs especially Amitriptyline Paroxetine All other SSRIs mild weight gain Weight Neutral SNRIs Trazodone Weight Loss Bupropion Sexual Side Effects Marked Paroxetine SSRIs (much less with vortioxetine and escitalopram) SNRIs TCAs MAOIs Mild Trazodone Mirtazapine None Bupropion 13

14 Insomnia Patients Mirtazapine More sedating at lower doses Trazodone Lower doses used for sleep and higher for depression Sedating effect dose increase with increased dose TCAs (especially amitriptyline) Chronic Pain Types of Pain: Fibromyalgia Neuropathic Pain Migraines Meds that are helpful: Duloxetine Venlafaxine TCAs 14

15 Elderly Patients Start low and go slow Highly sensitive to meds Preferred medications include: Citalopram Caution with cardiac issues Escitalopram Sertraline Mirtazapine Appetite Stimulant, Sleep Venlafaxine Bupropion No paroxetine or fluoxetine Caution with TCAs Adolescent Patients Fluoxentine is first line tx Second line include sertraline, citalopram, escitalopram, and venlafaxine TCAs show no effect Black box warning in adolescents Paroxetine with strongest warning 15

16 Prenatal Patients Risk to benefit assessment Sertraline, Fluoxetine and Citalopram are preferred Increased risk of cardiac malformation and persistent pulmonary HTN of the newborn (PPHN) Level II ultrasound recommended if 1 st trimester use SSRI doses may need to increase in pregnancy Paroxetine is Category D DO NOT use in pregnancy Associated with cardiac malformations Lactating Patients Most SSRIs are safe in breastfeeding Sertraline and Paroxetine with lowest breast milk secretion Safest to use Fluoxetine and Venlafaxine with highest secretion Wellbutrin with reports of seizures in infant Effects on breastfeeding infant Agitation Poor feeding 16

17 Renal Impairment Decreased dose often required Bupropion Duloxetine Paroxetine Venlafaxine Hepatic Impairment Decreased dose often required Nefazodone can cause hepatotoxicity Bupropion Citalopram Duloxetine Fluoxetine Nortriptyline Sertraline Venlafaxine 17

18 Length of Treatment 4-12 months Reassessment of life stressors Weaning period Starting, Switching and Stopping To Start Start with half of intended dose x 1 week, then increase to intended dose Max effect in 4-6 weeks with most meds To D/C Slowly taper off of the medication over 1-2 weeks Longer taper with SNRIs To Change Cross taper when changing to/from MAOI, TCA, or mirtazapine SSRI to SSRI or SSRI to/from SNRI can change to equivalent dose without cross taper 18

19 Resistant Treatment Maximize dosing prior to changing med or adding a second med Addition of a second antidepressant Addition of an atypical antipsychotic 19

20 Adjunct Therapy Psychotherapy/Counseling Exercise Support Groups Combo with above decreases total treatment time and decreases relapse risk Take Home Points Not all antidepressants are equal Customize your therapy Consider desired and undesired side effect profiles Use side effects to your advantage Remember special populations when treating Subtherapeutic doses expose to risk but not to benefit 20

21 Questions? References Bonin L and Moreland CS. Overview of Treatment for Pediatric Depression. In: UpToDate, Middleman AB(Ed), UpToDate, Waltham, MA. (Accessed on July 27, 2015.) Ciechanowski P. Unipolar Major Depression in Adults: Choosing Initial Treatment. In: UpToDate, Roy-Burn P(Ed), UpToDate, Waltham, MA. (Accessed on July 27, 2015.) Clark MS, Jansen KL, and Cloy JA. Treatment of Childhood and Adolescent Depression. Am Fam Physician Sep 1;86(5):

22 References Hirsh M and Birnbaum R. Antidepressant medication in adults: Switching and discontinuing medication. In: UpToDate, Roy-Burn PP(Ed), UpToDate, Waltham, MA. (Accessed on July 27, 2015.) Kovich H and Dejong A. Common Questions About the Pharmacologic Management of Depression in Adults. Am Fam Physician Jul 15;92(2): Maurer D and Darnall C. Screening for Depression. Am Fam Physician Jan 15;85(2: Roy-Burn P. Unipolar major depression in pregnant women: Treatment. In: UpToDate, Stein MB(Ed), UpToDate, Waltham, MA. (Accessed on July 27, 2015.) 22

Antidepressant Selection in Primary Care

Antidepressant Selection in Primary Care Antidepressant Selection in Primary Care R E B E C C A D. L E W I S, D O O O A S U M M E R C M E B R A N S O N, M O 1 5 A U G U S T 2 0 1 5 Objectives Understand the epidemiology of depression. Recognize

More information

Diagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD

Diagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD Diagnosis & Management of Major Depression: A Review of What s Old and New Cerrone Cohen, MD Why You re Treating So Much Mental Health 59% of Psychiatrists Are Over the Age of 55 AAMC 2014 Physician specialty

More information

Common Antidepressant Medications for Adults

Common Antidepressant Medications for Adults (and Citalopram (Celexa) Escitalopram (Lexapro) Fluoxetine (Prozac) Fluoxetine Weekly (Prozac Weekly) 20 in AM w/ food (10 mg in elderly or those w/ panic disorder) 20 40 40 (If age >60yo, max 20) 10 10

More information

Guidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

Guidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) Guidelines CH Lim, B Baizury, on behalf of Development Group Clinical Practice Guidelines Management of Major Depressive Disorder A. Introduction Major depressive

More information

Pharmaceutical Interventions. Collaborative Model of Mental Health Care for Older Iowans Des Moines May 18, 2007

Pharmaceutical Interventions. Collaborative Model of Mental Health Care for Older Iowans Des Moines May 18, 2007 Pharmaceutical Interventions Collaborative Model of Mental Health Care for Older Iowans Des Moines May 18, 2007 Outline Overview Overview of initial workup and decisions in elderly depressed individual

More information

Affective or Mood Disorders. Dr. Alia Shatanawi March 12, 2018

Affective or Mood Disorders. Dr. Alia Shatanawi March 12, 2018 Affective or Mood Disorders Dr. Alia Shatanawi March 12, 2018 Affective or Mood Disorders Reactive Depression. Secondary: Medical Neurological Drugs Major (Endogenous) Depression = Unipolar: Depressed

More information

Depression & Anxiety in Adolescents

Depression & Anxiety in Adolescents Depression & Anxiety in Adolescents Objectives 1) Review diagnosis of anxiety and depression in adolescents 2) Provide overview of evidence-based treatment options 3) Increase provider comfort level with

More information

KEY MESSAGES. It is often under-recognised and 30-50% of MDD cases in primary care and medical settings are not detected.

KEY MESSAGES. It is often under-recognised and 30-50% of MDD cases in primary care and medical settings are not detected. KEY MESSAGES Major depressive disorder (MDD) is a significant mental health problem that disrupts a person s mood and affects his psychosocial and occupational functioning. It is often under-recognised

More information

Depression in Pregnancy

Depression in Pregnancy TREATING THE MOTHER PROTECTING THE UNBORN A MOTHERISK Educational Program The content of this program reflects the expression of a consensus on emerging clinical and scientific advances as of the date

More information

Quick Guide to Common Antidepressants-Adults

Quick Guide to Common Antidepressants-Adults Quick Guide to Common Antidepressants-Adults Medication Therapeutic Range (mg/day) Initial Suggested Serotonin Reuptake Inhibitors (SSRIs) All available as generic FLUOXETINE (Prozac) CITALOPRAM (Celexa

More information

BRIEF ANTIDEPRESSANT OVERVIEW. Casey Gallimore, Pharm.D., M.S.

BRIEF ANTIDEPRESSANT OVERVIEW. Casey Gallimore, Pharm.D., M.S. BRIEF ANTIDEPRESSANT OVERVIEW Casey Gallimore, Pharm.D., M.S. Antidepressant Medication Classes First Generation Tricyclic Antidepressants (TCAs) Monoamine Oxidase Inhibitors (MAOIs) Second Generation

More information

Presentation is Being Recorded

Presentation is Being Recorded Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please

More information

Daniel Suzuki, MD Adjunct Clinical Associate Professor of Psychiatry, USC Keck School of Medicine Clinical Adjunct Professor/Faculty, Graduate School

Daniel Suzuki, MD Adjunct Clinical Associate Professor of Psychiatry, USC Keck School of Medicine Clinical Adjunct Professor/Faculty, Graduate School Daniel Suzuki, MD Adjunct Clinical Associate Professor of Psychiatry, USC Keck School of Medicine Clinical Adjunct Professor/Faculty, Graduate School of Psychology, Fuller Theological Seminary Medical

More information

9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded

9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please

More information

Children s Hospital Of Wisconsin

Children s Hospital Of Wisconsin Children s Hospital Of Wisconsin Co-Management Guidelines To support collaborative care, we have developed guidelines for our community providers to utilize when referring to, and managing patients with,

More information

Nortriptyline vs amitriptyline in elderly

Nortriptyline vs amitriptyline in elderly Nortriptyline vs amitriptyline in elderly Amitriptyline (Elavil ) vs other antidepressants - comparative analysis amitriptyline vs divalproate, amitriptyline vs trazodone. Learn what other patients are

More information

Anti-Depressant Medications

Anti-Depressant Medications Anti-Depressant Medications A Introduction: This topic may be a little bit underestimated here in Jordan, while in western countries it has more significance. The function of anti-depressants is to change

More information

Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist

Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Medication Dosage Indication for Use Aricept (donepezil) Exelon (rivastigmine) 5mg 23mg* ODT 5mg Solution

More information

Volume 4; Number 5 May 2010

Volume 4; Number 5 May 2010 Volume 4; Number 5 May 2010 CLINICAL GUIDELINES FOR ANTIDEPRESSANT USE IN PRIMARY AND SECONDARY CARE Lincolnshire Partnership Foundation Trust in conjunction with Lincolnshire PACEF have recently updated

More information

Mood Disorders.

Mood Disorders. Mood Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner

More information

Appendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over)

Appendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over) Appendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over) Introduction / Background Treatment comes after diagnosis Diagnosis is based on

More information

Adult Depression - Clinical Practice Guideline

Adult Depression - Clinical Practice Guideline 1 Adult Depression - Clinical Practice Guideline 05/2018 Diagnosis and Screening Diagnostic criteria o Please refer to Attachment A Screening o The United States Preventative Services Task Force (USPSTF)

More information

This initial discovery led to the creation of two classes of first generation antidepressants:

This initial discovery led to the creation of two classes of first generation antidepressants: Antidepressants - TCAs, MAOIs, SSRIs & SNRIs First generation antidepressants TCAs and MAOIs The discovery of antidepressants could be described as a lucky accident. During the 1950s, while carrying out

More information

Drugs for Emotional and Mood Disorders Chapter 16

Drugs for Emotional and Mood Disorders Chapter 16 Drugs for Emotional and Mood Disorders Chapter 16 NCLEX-RN Review Question 1 Choices Please note Question #1 at the end of Ch 16 pg 202 & Key pg 805 answer is #4 1. Psychomotor symptoms 2. Tachycardia,

More information

Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services

Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services DEPRESSION Pharmacological Treatment of Depression NICE guidelines suggest the following stepped care model also

More information

PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS. Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA

PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS. Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA CASE #1 PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA OBJECTIVES Epidemiology Presentation in older adults Assessment Treatment

More information

PHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES

PHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES PHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES Table of Contents Print TABLE OF CONTENTS Drug Page Number Anafranil... 2 Asendin... 4 Celexa... 4 Cymbalta... 6 Desyrel... 8 Effexor...10 Elavil...14

More information

Depression. There are several forms of depression (depressive disorders). Major depressive disorder and dysthymic disorder are the most common.

Depression. There are several forms of depression (depressive disorders). Major depressive disorder and dysthymic disorder are the most common. Depression Depression is a state of low mood and aversion to activity that can affect a person's thoughts, behavior, feelings and sense of well-being. People with depressed mood can feel sad, anxious,

More information

The Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders What are functional GI disorders?

The Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders What are functional GI disorders? The Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders Christine B. Dalton, PA-C Douglas A. Drossman, MD and Kellie Bunn, PA-C What are functional GI

More information

3. Atypical antidepressants

3. Atypical antidepressants 3. Atypical antidepressants Bupropion, mirtazapine, nefazodone & trazodone. Mixed group that act at several different sites. Bupropion Acts as a weak dopamine & NE reuptake inhibitor. Has short half-life.

More information

Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment

Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment Lisa Lloyd Giles, MD Medical Director, Behavioral Consultation, Crisis, and Community Services Primary Children s Hospital Associate Professor,

More information

Pharmacotherapy of depression

Pharmacotherapy of depression Pharmacotherapy of depression Stuff you already know Stuff you probably know Stuff you possibly don t know Stuff you thought you knew but are mistaken about How long does it take for antidepressants

More information

Partners in Care Quick Reference Cards

Partners in Care Quick Reference Cards Partners in Care Quick Reference Cards Supported by the Agency for Healthcare Research and Quality MR-1198/8-AHRQ R This project was funded by the Agency for Healthcare Research and Quality (AHRQ), formerly

More information

Antidepressants. Dr Malek Zihlif

Antidepressants. Dr Malek Zihlif Antidepressants The optimal use of antidepressant required a clear understanding of their mechanism of action, pharmacokinetics, potential drug interaction and the deferential diagnosis of psychiatric

More information

Realities of Depression in Primary Care Setting

Realities of Depression in Primary Care Setting Realities of Depression in Primary Care Setting Jaroslava Salman, MD Department of Supportive Care Medicine Division of Psychiatry Click to edit Master Presentation Date August 4 th 2018 Disclosure I have

More information

Optimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE

Optimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE Optimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE Chan-Hyung Kim, MD Severance Mental Health Hospital Institute of Behavioral Science in Medicine Diagnostic Criteria Pyramid Etiologic Pathophysiologic

More information

Joel V. Oberstar, M.D. 1

Joel V. Oberstar, M.D. 1 Diagnosis and Treatment of Depressive Disorders in Children and Adolescents Joel V. Oberstar, M.D. CEO & Chief Medical Officer Adjunct Assistant Professor of Psychiatry University of Minnesota Medical

More information

Antidepressant Medication Strategies We ve Come a Long Way or Have We? Who Writes Prescriptions for Psychotropic Medications. Biological Psychiatry

Antidepressant Medication Strategies We ve Come a Long Way or Have We? Who Writes Prescriptions for Psychotropic Medications. Biological Psychiatry Antidepressant Medication Strategies We ve Come a Long Way or Have We? Joe Wegmann, PD, LCSW The PharmaTherapist Joe@ThePharmaTherapist.com 504.587.9798 www.pharmatherapist.com Are you receiving our free

More information

Antidepressant Pharmacology An Overview

Antidepressant Pharmacology An Overview Figure 1. Antidepressant Pharmacology An Overview Source: NEJM 2005;353:1819-34 Figure 2. 1 Figure 3: Antidepressant Pharmacology pictures: Weak inhibition Bupropion NOTE: CYP enzymes noted are those inhibited

More information

Guidelines on Choice and Selection of Antidepressants for the Management of Depression

Guidelines on Choice and Selection of Antidepressants for the Management of Depression Guidelines on Choice and Selection of Antidepressants for the Management of Depression 1. Introduction This guidance should be considered as part of a stepped care approach in the management of depressive

More information

Prepared by: Elizabeth Vicens-Fernandez, LMHC, Ph.D.

Prepared by: Elizabeth Vicens-Fernandez, LMHC, Ph.D. Prepared by: Elizabeth Vicens-Fernandez, LMHC, Ph.D. Sources: National Institute of Mental Health (NIMH), the National Alliance on Mental Illness (NAMI), and from the American Psychological Association

More information

Elavil (amitriptyline)

Elavil (amitriptyline) Generic name: Amitriptyline Available strengths: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg tablets; 10 mg/ml injection Available in generic: Yes Drug class: Tricyclic antidepressant General Information

More information

Norpramin (desipramine)

Norpramin (desipramine) Generic name: Desipramine Available strengths: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg tablets Available in generic: Yes Drug class: Tricyclic antidepressant General Information Norpramin (desipramine)

More information

Treatment Options for Bipolar Disorder Contents

Treatment Options for Bipolar Disorder Contents Keeping Your Balance Treatment Options for Bipolar Disorder Contents Medication Treatment for Bipolar Disorder 2 Page Medication Record 5 Psychosocial Treatments for Bipolar Disorder 6 Module Summary 8

More information

Family Medicine Forum November 10, 2017 Montreal., Quebec. Jon Davine, CCFP, FRCP(C) Associate Professor, McMaster University

Family Medicine Forum November 10, 2017 Montreal., Quebec. Jon Davine, CCFP, FRCP(C) Associate Professor, McMaster University APPROACH TO DEPRESSION IN PRIMARY CARE Family Medicine Forum November 10, 2017 Montreal., Quebec. Jon Davine, CCFP, FRCP(C) Associate Professor, McMaster University DISCLOSURE Speaker/Presenter Disclosure

More information

Anxiety Disorders.

Anxiety Disorders. Anxiety Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner

More information

Depressive Disorders A clinical overview. Dr. Scott Yarosh, Medical Director, Behavioral Health

Depressive Disorders A clinical overview. Dr. Scott Yarosh, Medical Director, Behavioral Health Depressive Disorders A clinical overview Dr. Scott Yarosh, Medical Director, Behavioral Health Depressive Disorders What is depression? Complex series of conditions Physical component Emotional component

More information

Part 2: Pain and Symptom Management Depression

Part 2: Pain and Symptom Management Depression Guidelines & Protocols Advisory Committee Part 2: Pain and Symptom Management Depression Effective Date: February 22, 2017 Key Recommendations Before diagnosing and treating major depressive disorder,

More information

Treating Depression in Adults

Treating Depression in Adults Treating Depression in Adults By Deborah Christensen, Ph.D., M.S.C.P. Depressive Disorders represent a broad and heterogeneous group of commonly diagnosed psychological disorders. The DSM adequately describes

More information

TREATMENT OF DEPRESSION IN LATE LIFE. Robert Kohn, MD

TREATMENT OF DEPRESSION IN LATE LIFE. Robert Kohn, MD TREATMENT OF DEPRESSION IN LATE LIFE Robert Kohn, MD WHY TREAT ELDERLY PERSONS Major depression is not a normal part of aging The rates are lower than younger cohorts The prevalence rates are still high

More information

Guidelines on Choice and Selection of Antidepressants for the Management of Depression

Guidelines on Choice and Selection of Antidepressants for the Management of Depression Working in partnership: Hertfordshire Partnership University NHS Foundation Trust East and North Hertfordshire Clinical Commissioning Group Herts Valleys Clinical Commissioning Group Guidelines on Choice

More information

TREATING MAJOR DEPRESSIVE DISORDER

TREATING MAJOR DEPRESSIVE DISORDER TREATING MAJOR DEPRESSIVE DISORDER A Quick Reference Guide Based on Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Second Edition, originally published in April 2000.

More information

Chronic Pain Care Management in Primary Care 12/16/2010. Jürgen Unützer, MD, MPH, MA UW Psychiatry and Behavioral Sciences

Chronic Pain Care Management in Primary Care 12/16/2010. Jürgen Unützer, MD, MPH, MA UW Psychiatry and Behavioral Sciences CARE MANAGEMENT FOR CHRONIC PAIN Jürgen Unützer, MD, MPH, MA UW Psychiatry and Behavioral Sciences Dec 16, 2010 Agenda Physical and Emotional Pain Collaborative Care and Care Management for Pain Treatments

More information

Pamelor (nortriptyline)

Pamelor (nortriptyline) Generic name: Nortriptyline Available strengths: 10 mg, 25 mg, 50 mg, 75 mg capsules; 10 mg/5 ml oral solution Available in generic: Yes Drug class: Tricyclic antidepressant General Information Pamelor

More information

Antidepressant Treatment of Depression

Antidepressant Treatment of Depression Antidepressant Treatment of Depression PLEASE REFER TO INTEGRATED CARE PATHWAY FOR INFORMATION RELATING TO THE OVERALL MANAGEMENT OF DEPRESSION SSRI s are first choice agents because they are as effective

More information

Depression major depressive disorder. Some terms: Major Depressive Disorder: Major Depressive Disorder:

Depression major depressive disorder. Some terms: Major Depressive Disorder: Major Depressive Disorder: Depression major depressive disorder Oldest recognized disorder: melancholia It is a positive and active anguish, a sort of psychical neuralgia wholly unknown to normal life. - William James "I am now

More information

Treatment-resistant depression in primary care

Treatment-resistant depression in primary care Treatment-resistant depression in primary care Interprofessional CME, October 2017 Brian J. Mickey, MD, PhD Associate Professor School of Medicine Department of Psychiatry Disclosures Speakers bureau:

More information

Effective Health Care

Effective Health Care Number 7 Effective Health Care Comparative Effectiveness of Second- Generation Antidepressants in the Pharmacologic Treatment of Adult Depression Executive Summary Background Depressive disorders such

More information

ANTI-DEPRESSANT MEDICATIONS

ANTI-DEPRESSANT MEDICATIONS ANTI-DEPRESSANT MEDICATIONS This information is not intended to be a substitute for medical advice. It s purpose is solely informative. If your client or yourself are taking antidepressants, do not change

More information

FROM MEDICATION TO MINDFULNESS: NEW INSIGHTS INTO THE WORLD OF ANXIETY

FROM MEDICATION TO MINDFULNESS: NEW INSIGHTS INTO THE WORLD OF ANXIETY 13 th Pearl Leibovitch Clinical Day November 18th, 2014 Mounir H. Samy, MD, FRCP(C) Associate Professor of Psychiatry McGill University (ret.) FROM MEDICATION TO MINDFULNESS: NEW INSIGHTS INTO THE WORLD

More information

Pharmacists in Medication Adherence in Psychiatric Patients

Pharmacists in Medication Adherence in Psychiatric Patients Pharmacists in Medication Adherence in Psychiatric Patients Mamta Parikh, PharmD, BCPS, BCPP Assistant Professor, Clinical and Administrative Sciences Notre Dame of Maryland University School of Pharmacy

More information

A Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer

A Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer A Brief Overview of Psychiatric Pharmacotherapy Joel V. Oberstar, M.D. Chief Executive Officer Disclosures Some medications discussed are not approved by the FDA for use in the population discussed/described.

More information

Consultant Pharmacist Approach to Major Depressive Disorder

Consultant Pharmacist Approach to Major Depressive Disorder Consultant Pharmacist Approach to Major Depressive Disorder ALAN OBRINGER RPH, CPH, CGP PRESIDENT/OWNER GUARDIAN PHARMACY OF ORLANDO Objectives What is Depression? Discuss the epidemiology of depression

More information

Consultant Pharmacist Approach to Major Depressive Disorder ALAN OBRINGER RPH, CPH, CGP PRESIDENT/OWNER GUARDIAN PHARMACY OF ORLANDO

Consultant Pharmacist Approach to Major Depressive Disorder ALAN OBRINGER RPH, CPH, CGP PRESIDENT/OWNER GUARDIAN PHARMACY OF ORLANDO Consultant Pharmacist Approach to Major Depressive Disorder ALAN OBRINGER RPH, CPH, CGP PRESIDENT/OWNER GUARDIAN PHARMACY OF ORLANDO Objectives What is Depression? Discuss the epidemiology of depression

More information

Depression. University of Illinois at Chicago College of Nursing

Depression. University of Illinois at Chicago College of Nursing Depression University of Illinois at Chicago College of Nursing 1 Learning Objectives Upon completion of this session, participants will be better able to: 1. Recognize depression, its symptoms and behaviors

More information

Treatment of Major Depressive Disorder

Treatment of Major Depressive Disorder Treatment of Major Depressive Disorder Sarah Mullowney, MD PGY3 Psychiatry Resident, University of Utah Paula Gibbs, MD Medical Director of 5 West at UUMC Clerkship Director MS III Psychiatric Rotation

More information

Austedo. (deutetrabenazine) New Product Slideshow

Austedo. (deutetrabenazine) New Product Slideshow Austedo (deutetrabenazine) New Product Slideshow Introduction Brand name: Austedo Generic name: Deutetrabenazine Pharmacological class: Vesicular monoamine transporter 2 (VMAT2) inhibitor Strength and

More information

Psychiatry curbside: Answers to a primary care doctor s top mental health questions

Psychiatry curbside: Answers to a primary care doctor s top mental health questions Psychiatry curbside: Answers to a primary care doctor s top mental health questions April 27, 2018 Laurel Ralston, DO Psychiatrist, Taussig Cancer Institute Objectives Review current diagnostic and prescribing

More information

Anxiety Disorders- OCD. Peter Giacobbe MD FRCPC L. Ravindran MD FRCPC

Anxiety Disorders- OCD. Peter Giacobbe MD FRCPC L. Ravindran MD FRCPC Anxiety Disorders- OCD Peter Giacobbe MD FRCPC L. Ravindran MD FRCPC Anxiety Disorders - Epidemiology Anxiety disorders are the most common class of mental disorders Estimated lifetime prevalence rates

More information

Management of SSRI Induced Sexual Dysfunction. Serotonin Reuptake Inhibitors*

Management of SSRI Induced Sexual Dysfunction. Serotonin Reuptake Inhibitors* Management of SSRI Induced Sexual Dysfunction John J. Miller, M.D. Medical Director, Center for Health and WellBeing Exeter, NH Serotonin Reuptake Inhibitors* fluoxetine clomipramine sertraline paroxetine

More information

Medications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation

Medications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation Medications for Anxiety & Behavior in Williams Syndrome Christopher J. McDougle, M.D. Director, Lurie Center for Autism Professor of Psychiatry and Pediatrics Massachusetts General Hospital and MassGeneral

More information

Primary Care Management of Depression. John Briles, MD, Medical Director October 11, 2017

Primary Care Management of Depression. John Briles, MD, Medical Director October 11, 2017 John Briles, MD, Medical Director October 11, 2017 Molina Healthcare of Michigan uses a HEDIS measure for Antidepressant Medication Management (AMM) to measure how well treating providers (PCPs) appropriately

More information

Depression: Identification, Evaluation and Management in Primary Care

Depression: Identification, Evaluation and Management in Primary Care Depression: Identification, Evaluation and Management in Primary Care Primary Care Medicine: Update 2010 Rena K. Fox, M.D. Associate Professor of Clinical Medicine University of California, San Francisco

More information

Mentoring Session: Participant Cases

Mentoring Session: Participant Cases Handout for the Neuroscience Education Institute (NEI) online activity: Mentoring Session: Participant Cases The Case: 55-year-old patient with depression and anxiety The Question: What to do when antidepressants

More information

Reviews/Evaluations. Use of Selective Serotonin Reuptake Inhibitors in Pediatric Patients. Pharmacotherapeutic Options

Reviews/Evaluations. Use of Selective Serotonin Reuptake Inhibitors in Pediatric Patients. Pharmacotherapeutic Options Reviews/Evaluations Use of Selective Serotonin Reuptake Inhibitors in Pediatric Patients Childhood major depressive disorder (MDD) has become recognized as a serious and common illness affecting between

More information

Perinatal Mental Health: Prescribing Guidance for Trust Prescribers and GPs

Perinatal Mental Health: Prescribing Guidance for Trust Prescribers and GPs Perinatal Mental Health: Prescribing Guidance for Trust Prescribers and GPs (Version 3 January 2015) Principal Author: Dr Jenny Cooke Consultant Psychiatrist, Brighton & Hove Perinatal Mental Health Service

More information

Disclosures. Overview of Workshop. Objectives. Medical Care of Vulnerable and Underserved Populations: Advanced Cases in Anxiety and Depression

Disclosures. Overview of Workshop. Objectives. Medical Care of Vulnerable and Underserved Populations: Advanced Cases in Anxiety and Depression Medical Care of Vulnerable and Underserved Populations: Advanced Cases in Anxiety and Depression Disclosures The speakers have no disclosures. Lisa Ochoa-Frongia, MD Christina Mangurian, MD, MAS L. Elizabeth

More information

Tofranil and Tofranil-PM (imipramine)

Tofranil and Tofranil-PM (imipramine) Tofranil and Tofranil-PM (imipramine) Generic name: Imipramine Available strengths: 10 mg, 25 mg, 50 mg tablets; 75 mg, 100 mg, 125 mg, 150 mg capsules (Tofranil-PM) Available in generic: Yes Drug class:

More information

Does cymbalta cause weight gain

Does cymbalta cause weight gain Does cymbalta cause weight gain Search 17-3-2015 Cymbalta (duloxetine) is an antidepressant that comes with many side effects. Is weight gain one? See what research says about the drug and weight. 4-4-2013

More information

Antidepressants Choosing the Right One

Antidepressants Choosing the Right One Antidepressants Choosing the Right One Dr Lim Boon Leng Consultant Psychiatrist Dr BL Lim Centre For Psychological Wellness #09-09, Gleneagles Medical Centre, 6 Napier Rd, S258499 www.psywellness.com.sg

More information

Medication management of anxiety & depression. Dr Katie Simpson GP Mental health lead East Berks CCG

Medication management of anxiety & depression. Dr Katie Simpson GP Mental health lead East Berks CCG Medication management of anxiety & depression Dr Katie impson GP Mental health lead East Berks CCG NICE guidelines for Anxiety tepped Care RIs and NRIs in Anxiety disorders RI ertraline Citalopram Fluoxetine

More information

Disclosure Information

Disclosure Information Disclosure Information I have no financial relationships to disclose. I will discuss the off label use of several depression and anxiety medications in pediatric population Pediatric Depression & Anxiety

More information

Psychiatry in Primary Care: What is the Role of Pharmacist?

Psychiatry in Primary Care: What is the Role of Pharmacist? Psychiatry in Primary Care: What is the Role of Pharmacist? Benjamin Chavez, PharmD, BCPP, BCACP Clinical Associate Professor Director of Behavioral Health Pharmacy Services January 12, 2019 Disclosure

More information

A Basic Approach to Mood and Anxiety Disorders in the Elderly

A Basic Approach to Mood and Anxiety Disorders in the Elderly A Basic Approach to Mood and Anxiety Disorders in the Elderly November 1 2013 Sarah Colman MD FRCPC Clinical Fellow, Geriatric Psychiatry Mount Sinai Hospital, University of Toronto Disclosure No conflict

More information

Bupropion HCl, bupropion hydrobromide Wellbutrin SR, Wellbutrin XL, Zyban, Aplenzin, Forfivo XL

Bupropion HCl, bupropion hydrobromide Wellbutrin SR, Wellbutrin XL, Zyban, Aplenzin, Forfivo XL Bupropion Generic names Available brands Available strengths and formulations Available in generic Bupropion HCl, bupropion hydrobromide Wellbutrin SR, Wellbutrin XL, Zyban, Aplenzin, Forfivo XL 75-mg

More information

Psychiatric Medication Guide

Psychiatric Medication Guide Psychiatric Medication Guide F O R : N E O N P R I M A R Y H E A L T H C A R E P R O V I D E R S B Y : M I C H E L L E R O M E R O, D O M A Y, 2 0 1 3 Anti-depressants TCA s & MAOI s (Tricyclic Antidepressants

More information

How to Manage Anxiety

How to Manage Anxiety How to Manage Anxiety Dr Tony Fernando Psychological Medicine University of Auckland Auckland District Health Board www.insomniaspecialist.co.nz www.calm.auckland.ac.nz Topics How to diagnose How to manage

More information

REBOXETINE. THERAPEUTICS Brands Norebox Edronax see index for additional brand names. Generic? No

REBOXETINE. THERAPEUTICS Brands Norebox Edronax see index for additional brand names. Generic? No REBOXETINE THERAPEUTICS Brands Norebox Edronax see index for additional brand names Generic? No Class Neuroscience-based Nomenclature: norepinephrine reuptake inhibitor (N-RI) Selective norepinephrine

More information

Major Depression and Anxiety in Adolescents and Adults

Major Depression and Anxiety in Adolescents and Adults Major Depression and Anxiety in Adolescents and Adults Miggie Greenberg, M.D. Associate Professor of Psychiatry St. Louis University School of Medicine greenbml@slu.edu *NO DISCLOSURES* OBJECTIVES * Recognize

More information

ANTIDEPRESSANTS IN USE IN CLINICAL PRACTICE

ANTIDEPRESSANTS IN USE IN CLINICAL PRACTICE Medicinska naklada - Zagreb, Croatia Conference paper ANTIDEPRESSANTS IN USE IN CLINICAL PRACTICE Mark Agius 1 & Hannah Bonnici 2 1 Clare College, University of Cambridge, Cambridge, UK 2 Hospital Pharmacy

More information

VA/DoD Clinical Practice Guideline for Management of Post Traumatic Stress. Core Module

VA/DoD Clinical Practice Guideline for Management of Post Traumatic Stress. Core Module VA/DoD Clinical Practice Guideline for Management of Post Traumatic Stress Core Module Module A Acute Stress Continue Treatment for ASD Treatment for ACUTE Stress Disorder Module B PTSD Continue Treatment

More information

Guilt Suicidality. Depression Co-Occurs with Medical Illness The rate of major depression among those with medical illness is significant.

Guilt Suicidality. Depression Co-Occurs with Medical Illness The rate of major depression among those with medical illness is significant. 1-800-PSYCH If you are obsessive-compulsive, dial 1 repeatedly If you are paranoid-delusional, dial 2 and wait, your call is being traced If you are schizophrenic, a little voice will tell you what number

More information

Major Depressive Disorder

Major Depressive Disorder Major Depressive Disorder HEDIS Measures And Clinical Practice Guidelines Jennifer Highley, PMHNP-BC Behavioral Health West Point Healthcare Effectiveness Data and Information Set (HEDIS) Performance measures

More information

Linda Sobeski Farho, PharmD, BCPS Assistant Professor, Pharmacy Practice UNMC College of Pharmacy Critical Issues in Geriatrics June 24, 2010

Linda Sobeski Farho, PharmD, BCPS Assistant Professor, Pharmacy Practice UNMC College of Pharmacy Critical Issues in Geriatrics June 24, 2010 Pharmacologic Treatment of Depression Linda Sobeski Farho, PharmD, BCPS Assistant Professor, Pharmacy Practice UNMC College of Pharmacy Critical Issues in Geriatrics June 24, 2010 1 Disclosure I have no

More information

Acute Treatment: 40 mg/day (20 mg twice daily) to 60 mg/day (once daily or as 30 mg twice daily); Maintenance Treatment: 60 mg/day

Acute Treatment: 40 mg/day (20 mg twice daily) to 60 mg/day (once daily or as 30 mg twice daily); Maintenance Treatment: 60 mg/day 1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Cymbalta safely and effectively. See full prescribing information for Cymbalta. Cymbalta (duloxetine

More information

ESCITALOPRAM. THERAPEUTICS Brands Lexapro see index for additional brand names. Generic? Yes

ESCITALOPRAM. THERAPEUTICS Brands Lexapro see index for additional brand names. Generic? Yes ESCITALOPRAM THERAPEUTICS Brands Lexapro see index for additional brand names Generic? Yes Class SSRI (selective serotonin reuptake inhibitor); often classified as an antidepressant, but it is not just

More information

Depression: Assessment and Treatment For Older Adults

Depression: Assessment and Treatment For Older Adults Tool on Depression: Assessment and Treatment For Older Adults Based on: National Guidelines for Seniors Mental Health: the Assessment and Treatment of Depression Available on line: www.ccsmh.ca www.nicenet.ca

More information

Elements for a Public Summary

Elements for a Public Summary VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Generalised anxiety disorder Generalised anxiety disorder (GAD) is an umbrella term that covers a wide range of anxiety disorders

More information

TRANYLCYPROMINE. THERAPEUTICS Brands Parnate see index for additional brand names. Generic? Yes

TRANYLCYPROMINE. THERAPEUTICS Brands Parnate see index for additional brand names. Generic? Yes TRANYLCYPROMINE THERAPEUTICS Brands Parnate see index for additional brand names Generic? Yes Class Monoamine oxidase inhibitor (MAOI) Commonly Prescribed for (bold for FDA approved) Major depressive episode

More information

Depression in the Medically Ill

Depression in the Medically Ill Mayo School of Continuous Professional Development Psychiatry in Medical Settings February 9 th, 2017 Depression in the Medically Ill David Katzelnick, M.D. Professor of Psychiatry, Mayo Clinic College

More information